Heart Drug Memantine Cuts Dangerous Irregular Heartbeats by Nearly Half
Clinical trial shows memantine reduces premature atrial contractions by 47% and prevents atrial fibrillation in heart patients.
Summary
A groundbreaking clinical trial found that memantine, a drug typically used for dementia, dramatically reduces dangerous irregular heartbeats called premature atrial contractions (PACs). In 241 patients with frequent PACs, memantine reduced these abnormal beats by 47% more than placebo over six weeks. Most importantly, only 5% of memantine patients developed atrial fibrillation compared to 24% taking placebo. PACs increase risks of stroke, heart failure, and atrial fibrillation. This represents the first approved pharmacological approach for PAC suppression, targeting a newly discovered cardiac glutamate system rather than traditional ion channels.
Detailed Summary
Premature atrial contractions (PACs) are irregular heartbeats that significantly increase risks of atrial fibrillation, stroke, and heart failure. Despite these serious consequences, no medications have been approved specifically to suppress PACs, leaving patients with limited treatment options.
Researchers conducted a rigorous phase 2 clinical trial testing memantine, an Alzheimer's drug that blocks glutamate receptors in the brain. Scientists recently discovered that heart tissue also contains glutamate receptors that regulate electrical activity. The study enrolled 241 adults with frequent, symptomatic PACs across multiple medical centers.
Participants received either memantine or placebo for six weeks in a double-blind design. Memantine reduced PAC frequency by 47 percentage points more than placebo, with over half of patients experiencing at least 50% reduction in irregular beats. Most remarkably, only 4.8% of memantine patients developed new atrial fibrillation compared to 23.9% in the placebo group.
These findings represent a paradigm shift in cardiac care, introducing the first non-ion channel approach to treating heart rhythm disorders. For health-conscious individuals, this research highlights how repurposing existing medications can unlock new therapeutic pathways. The dramatic reduction in atrial fibrillation risk is particularly significant for longevity, as this condition substantially increases stroke risk and cardiovascular mortality.
However, this was a relatively short six-week study, and longer-term safety and efficacy data are needed. The research focused on patients with frequent PACs, so benefits for those with occasional irregular beats remain unclear.
Key Findings
- Memantine reduced premature atrial contractions by 47% more than placebo over 6 weeks
- Only 5% of memantine patients developed atrial fibrillation vs 24% taking placebo
- 52% of patients had at least 50% reduction in irregular heartbeats with memantine
- No serious drug-related side effects occurred during the 6-week treatment period
- First medication to successfully target cardiac glutamate system for heart rhythm control
Methodology
Phase 2, multicenter, randomized, double-blind, placebo-controlled trial with 241 symptomatic adults having frequent PACs (≥1000/24 hours). Participants received memantine or placebo for 6 weeks with continuous heart rhythm monitoring.
Study Limitations
Study duration was only 6 weeks, limiting long-term safety and efficacy assessment. Results apply specifically to patients with frequent PACs, and broader applicability to occasional irregular beats is unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.